- Verastem (NASDAQ:VSTM) submits marketing authorization application (MAA) to the European Medicines Agency (EMA) for COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), seeking approval for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and relapsed or refractory follicular lymphoma.
- Shares are up 3% premarket.
Verastem submits marketing application in Europe for Copiktra
Recommended For You
About VSTM Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
VSTM | - | - |
Verastem, Inc. |